Kiadis Pharma is an oncology focused biopharmaceutical development company with products in different phases of clinical development.
The company develops products that offer novel treatment options for terminally ill cancer patients addressing high unmet medical needs. The key focus of Kiadis Pharma is to overcome current limitations and complications of hematopoietic stem cell transplantation (HSCT) procedures for the treatment of blood cancer patients.
We have started our registration study for ATIRTM, a cell based therapeutic product allowing a new treatment opportunity for terminal blood cancer patients how cannot find a donor and have no options left.
In addition, please look here regarding an interview with the first patient treated in this multinational registration study in Canada at the site of our lead physician Dr. Denis Claude Roy in Montreal.
Kiadis Pharma is headquartered in Amsterdam, The Netherlands.
This site provides information about the products in development, clinical programs, platform technologies and partners that will enable Kiadis Pharma to realize its ambitions.
Manja Bouman, CEO
